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Background:  Amiodarone (A) and sotalol (S) are widely used for the management of atrial fibrillation (AF), but their long-term use is complicated 
by the risk of extra-cardiac toxicities (A) and ventricular proarrhythmia (S), which may affect patient compliance. However, few data are available on 
real-world treatment persistence and AE frequencies among AF patients on A or S.
Methods:  In this retrospective cohort study, patients aged ≥18 years with a pharmacy claim for oral A or S between 2004 and 2007 were 
identified from the US MarketScan® claims databases. Eligibility criteria also included ≥1 inpatient or outpatient claims with an AF diagnosis <90 
days before or on the day of the earliest pharmacy claim (‘index’) and ≥12 months’ continuous enrollment before and following the index claim. 
Treatment persistence was assessed post-index. Frequencies of prespecified AEs and AF-related hospitalization were compared pre- vs post-index.
Results:  Of 3,459 eligible AF patients, 2,392 (mean age 72.2 years; 63% male) received A and 1,067 (mean age 67.5 years; 60% male) received 
S. Persistence 12 months post-index was higher with S (53.2%) than A (30.6%; P<0.001). Cardiovascular AEs increased post- vs pre-index with A and 
S (Table). AF-related admissions declined post-index with A, but rose with S.
Potential adverse event
(% patients)
Amiodarone (n=2,392) Sotalol (n=1,067)
Pre-index Post-index Pre-index Post-index
AF-related hospitalization 4.9 3.6* 5.6 8.0*
Cardiovascular AEs 43.1 55.8*** 31.0 44.2***
Torsade de pointes 7.0 8.2* 5.1 5.9
Bradycardia 7.1 10.9*** 9.1 14.4***
QT interval prolongation 12.1 17.1*** 10.9 18.1***
Atrioventricular block 1.7 2.6* 2.2 2.0
Ventricular tachycardia 1.3 1.6 0.9 2.2*
Heart failure 30.7 40.7*** 14.2 17.4**
Inpatient cardiovascular AEs 22.1 22.4 12.5 16.1*
Pulmonary AEs 2.4 4.1*** 2.0 2.3
Neurological AEs 2.2 2.2 1.8 1.5
Endocrinological AEs 1.1 2.9*** 1.7 2.5
Gastrointestinal AEs 1.1 1.6 0.5 0.9
Ophthalmological AEs 1.2 2.8*** 1.6 0.9
* P≤0.05 post- vs pre-index
** P≤0.01 post- vs pre-index
*** P≤0.001 post- vs pre-index
Conclusions:  Patients experience a high AE burden (particularly CV) with A and S and many discontinue treatment during the first year. Potential 
differences exist in AF-related hospitalization rates with A and S.
